All lobbying filings

TERUMO BCT, INC.

Lobbying for TERUMO BCT, INC. · Medical technology company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Colorado · House · Senate · $20,000.00 expenses · posted Oct 21, 2025

Official filing document

Bills named in this filing 5

S 721
Sickle Cell Disease Comprehensive Care Act
S 752
Accelerating Kids’ Access to Care Act
HR 1509
Accelerating Kids’ Access to Care Act of 2025
S 735
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
HR 1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Lobbying activity 2

Trade (domestic/foreign)

Global trade and tariffs

Health Issues

S.721 - SCD Comprehensive Care Act S.752/H.R.1509 - Accelerating Kids Access to Care Act S.735/H.R. 1796 - Reauthorization of Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 Blood and cell collection, storage, and processing Blood donation supply and quality

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.